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Introduction
Blastomycosis is caused by the dimorphic fungus Blastomyces 
dermatitidis.  Blastomycosis is an endemic mycosis that occurs 
in defined geographic areas and usually in regions that are warm 
with soil rich in organic debris, such as decaying vegetation 
and decomposed wood [1, 2].  In North America, blastomycosis 
usually occurs in the southeastern and south-central states 
that border the Mississippi and Ohio Rivers, the midwestern 
states and Canadian provinces that border the Great Lakes 
and Saint Lawrence Riverway [1-5].  Blastomycosis is a 
systemic pyogranulomatous infection.  The clinical spectrum of 
blastomycosis is varied, including asymptomatic infection, 
acute or chronic pneumonia, extrapulmonary and disseminated 
disease.  The lungs are the most common site of infection, 
followed by the skin, bones, and genitourinary system.  A subset 
of individuals with acute pulmonary blastomycosis can progress 
to fulminant multi-lobar pneumonia and acute respiratory 
distress syndrome [10].  Diagnostic delays are not uncommon 
and often result in increased morbidity and mortality.  Here, 
we describe a case of progressive pulmonary blastomycosis in a 
young healthy adult.
Case Report
A 31 year-old African American female with no significant past 
medical history presented to an outside hospital complaining 
of 1-week history of subjective fevers and chills, fatigue, 
nonproductive cough, dyspnea and left sided pleuritic chest 
pain.
Initial vital signs were temperature 100.5ºF, heart rate 95 
beats per minute, respiratory rate 18 breaths per minute, 
blood pressure 148/88 mm Hg, and oxygen saturation 99% on 
room air.  On physical exam, she had no respiratory distress, 
no lymphadenopathy, examination of the respiratory system 
revealed bilateral vesicular breath sounds and crackles at the 
left lower lobe. Examination of the cardiovascular system, 
abdomen, central nervous system, and skin were unremarkable. 
Initial diagnostic laboratory work up showed leucocyte 
count of 14,500 cells/mm3 (76% segmented neutrophils, 13% 
lymphocytes and 11% monocytes), hemoglobin 12.9 g/dl, 
hematocrit 38.9% and platelet count 316,000/mm3.  Serum 
electrolytes, renal function, and liver function tests were 
normal.  Rapid Influenza test was positive for Influenza A. 
Urine streptococcal and legionella antigens were negative. 
Chest X-ray (CXR) showed an ovoid superior segment left lower 
lobe focus of consolidation (Figure 1). 
A diagnosis of Influenza A and possible community acquired 
bacterial pneumonia was made and patient was admitted to the 
hospital.  She was started on oral oseltamivir and intravenous 
ceftriaxone and azithromycin. 
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Due to a lack of clinical improvement after three days of 
antimicrobial treatment, chest computed tomographic 
(CT) scan was obtained that showed a dense consolidation 
involving the majority of the left lower lobe, and a trace left 
pleural effusion (Figure 2).  Bronchoscopy was performed. 
Bronchoscopy did not show any endobronchial lesions, Gram’s 
stain of bronchoalveolar lavage (BAL) of left lower lobe showed 
many white blood cells and rare Gram-positive bacilli, culture 
grew 10,000-100,000 CFU/mL of normal respiratory flora, 
KOH Prep was negative for fungal elements, acid-fast bacilli was 
negative, as was legionella PCR.  BAL sample was not sent for 
cytological analysis.  She was hospitalized for five days during 
which there was no significant change in her clinical status and 
she remained without clinical improvement or deterioration. 
She completed a five day course of oral oseltamivir.  Intravenous 
antimicrobials were switched to oral levofloxacin to complete 
a course of seven days and she was discharged home with 
outpatient follow up. 
Figure 1. Initial Chest X-ray (CXR) showing ovoid superior segment left 
lower lobe consolidation.  
Figure 2. Chest computed tomographic (CT) scan showing dense 
consolidation involving the majority of the left lower lobe and trace left 
pleural effusion.
After discharge from hospital, she reported worsening of her 
symptoms and complained of fevers and chills, productive 
cough with hemoptysis, dyspnea, pleuritic left sided chest 
pain and worsening fatigue. She presented to our hospital for 
evaluation of these symptoms about four days after discharge 
from an outside hospital. 
Vital signs at the time of initial evaluation in our emergency 
department were as follows: temperature 102.0ºF, heart rate 
115 beats per minute, respiratory rate 20 per minute, blood 
pressure 126/66 mm Hg, and oxygen saturation 95% on 
room air.  On physical exam, she had no respiratory distress, 
no lymphadenopathy, examination of the respiratory system 
revealed diminished breath sounds, whisper pectoriloquy, 
egophony and crackles at the left lower lobe, examination of the 
cardiovascular system, abdomen, central nervous system and 
skin were unremarkable. 
Pertinent initial diagnostic laboratory work up showed leucocyte 
count of 33.3 x 103 cells/mm3 (83% segmented neutrophils, 
12% lymphocytes and 4% monocytes).  Hemoglobin 11.5 g/
dl, hematocrit 34% and platelet count 539,000/mm3.  Serum 
electrolytes revealed serum sodium 139 mmol/L, potassium of 
3.1 mmol/L, renal function revealed blood urea nitrogen and 
serum creatinine of 6.0 mg/dL and 0.46 mg/dL respectively, 
liver function tests revealed alkaline phosphatase 255 U/L, AST 
145 U/L, ALT 110 U/L, albumin 3.1 g/dL, and total bilirubin 1.0 
mg/dL. 
Chest X-ray (CXR) showed progression of the radiological 
changes, in the intervening 10 days from the initial imaging, with 
a new development of worsening left lower lobe consolidation 
with cavitary changes consistent with necrotizing pneumonia 
(Figure 3). 
Chest computed tomography (CT) scan was obtained that 
showed dense necrotizing bronchopneumonia throughout left 
lower lobe, with left hilar, central mediastinal lymphadenopathy, 
and “tree-in-bud” reticulonodularity identified throughout 
the remainder of the lungs with scattered areas of non-
cavitary satellite nodularity, these findings likely representing 
manifestations of endobronchial spread of infection throughout 
the lungs (Figure 4).
Figure 3. Chest X-ray (CXR) showing left lower lobe consolidation with 
cavitary changes consistent with necrotizing pneumonia.
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The patient was admitted to the hospital with a diagnosis of non-
resolving pneumonia.  She was started on empiric intravenous 
vancomycin and piperacillin/tazobactam.  Sputum Gram’s 
stain showed Gram-positive cocci in pairs and sputum culture 
grew 2+ indigenous oral flora.  Sputum for acid-fast bacilli was 
negative, as was MRSA nasal PCR, viral respiratory panel, serum 
interferon gamma release assay, human immunodeficiency 
virus serology, urine streptococcal and legionella antigens, and 
blood cultures.  Procalcitonin level was 0.3 ng/mL.
Bronchoscopy was performed, it did not show any endobronchial 
lesions.  A large amount of purulent secretions were seen at 
the superior segment of left lower lobe which were suctioned 
out without difficulty.  Bronchoalveolar lavage (BAL) and 
transbronchial lung biopsies were obtained from left lower lobe 
segments.
Despite being on intravenous antibiotics for four days, she 
developed worsening of her clinical status.  Repeat chest 
X-ray (CXR) and chest computed tomographic (CT) scan were 
obtained that showed worsening pneumonia with complete 
consolidation of the left lower lobe and new patchy consolidation 
and nodules in the right lung as shown in Figure 5 and Figure 
6 respectively. Additional laboratory work up including fungal 
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Figure 4. Chest computed tomographic (CT) scan showing dense necrotizing bronchopneumonia seen throughout left lower lobe with left hilar, 
central mediastinal lymphadenopathy, and “tree-in-bud” reticulonodularity identified throughout the remainder of lungs with scattered areas of 
non-cavitary satellite nodularity.
Figure 5. Chest X-ray (CXR) showing persistent diffuse bilateral 
pneumonia, left greater than right, with a moderate left-sided pleural 
effusion.
Figure 6. Chest computed tomographic (CT) scan showing worsening diffuse pneumonia with complete consolidation of the left lower lobe, new 
patchy consolidation in the left upper lobe/lingula and right lower lobe and new/enlarging nodules in the right lung.  New small left pleural effusion 
with fluid in the fissure and layering over the apex.
blood cultures, urine Histoplasma antigen, serum Aspergillus 
Galactomannan antigen by EIA, serum (1-3)-Beta-D-Glucan, 
serum Coccidioides immitis antibodies were ordered.  Fungal 
blood cultures, Aspergillus Galactomannan antigen, serum 
Coccidioides immitis antibodies were negative. Urine 
Histoplasma antigen was detected and (1-3)-Beta-D-Glucan 
was strongly positive at >500 pg/mL. (Less than 60 pg/mL 
are interpreted as negative.  60 to 79 pg/mL are interpreted as 
indeterminate).
Patient was empirically started on IV amphotericin B.  The 
transbronchial lung biopsy results from the left lower lobe 
returned and showed numerous lymphocytes, histiocytes, many 
multinucleated giant cells, forming ill-defined granulomas.  The 
biopsy also revealed the presence of thick-walled single yeast 
forms of approximately 8–15 µm in size as shown in Figure 7a. 
The organisms stained positively with Gomori methenamine 
silver (GMS) stain as shown in Figure 7b.  Some of these 
yeast forms showed eccentric broad-based budding, overall 
morphology was consistent with blastomycosis.  Bronchial 
biopsy and BAL cultures using Sabouraud Dextrose Agar (SDA) 
showed growth of fungus as shown in Figures 8a, 8b and 8c. 
The patient showed significant clinical improvement on 
antifungal treatment. She was treated with amphotericin for 2 
weeks followed by oral itraconazole. She tolerated the treatment 
well without any side effects. Follow-up imaging of the lungs 
showed resolution of the pulmonary lesions.
Figure 7a. Hematoxylin-and-eosin-stained section of left lower lobe 
lung biopsy, low-power (Bottom) and high-power (Top) magnification, 
shows numerous lymphocytes, histiocytes, many multinucleated giant 
cells, forming ill-defined granulomas and presence of thick-walled single 
yeast forms of approximately 8–15 µm in size with eccentric broad-based 
budding overall morphology consistent with blastomycosis.
Figure 7b. Gomori methenamine silver (GMS) (1000X magnification) 
stain shows a budding yeast of Blastomyces dermatitidis with the 
characteristic broad-based bud.
Figure 8a. Phase-contrast microscopy: (1000X magnification): Shows 
the typical appearance of Blastomyces dermatitidis. Round to oval shape, 
thick, doubly refractile cell wall, and single broad-based bud. 
Discussion
In this case report, we have described a case of progressive 
acute pulmonary blastomycosis in a healthy adult living in 
Kentucky, initially presenting with flu like illness with a left 
sided consolidation on chest x-ray.  This review focuses on the 
epidemiological, clinical, diagnostic, and therapeutic aspects of 
blastomycosis.
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Figure 8b. Lacto-Phenol-Cotton-Blue Stain (LPCB) (1000X magnification): 
Shows the mold form of Blastomyces dermatitidis characterized by 
delicate, septate hyphae, unbranched conidiophores of rather short, yet 
varying length extending from the hyphae. Conidia are produced singly at 
the apex of the conidiophore or develop directly on the hyphae. Conidia are 
unicellular, round to pyriform (tear drop) in shape (~2 to 10 µm dia.). Conidia 
at the terminal end of the conidiophore resemble a “lollipop” in structure. 
Figure 8c. Bronchial and BAL culture using Sabouraud Dextrose Agar 
(SDA): Blastomyces dermatitidis takes 2 to 3 weeks to grow at 25 to 30 
degrees C. Blastomyces dermatitidis appears as white to beige cottony, 
mold (mycelium) on Sabouraud dextrose agar.
Epidemiology
Most cases of blastomycosis have been reported in North 
America.  Endemic areas include the southeastern and south-
central states bordering the Mississippi and Ohio River basins, 
the midwestern states and Canadian provinces bordering the 
Great Lakes and Saint Lawrence Riverway [1-5].  Outside of 
North America, blastomycosis has been reported in Africa with 
occasional cases reported from Mexico, Central and South 
America, India, and the Middle East.
Mycology
Blastomyces dermatitidis is a thermally dimorphic fungus.  It 
grows as the mycelial phase at room temperature and as the 
yeast phase at 37ºC.  This dimorphism appears to result from 
a hybrid histidine kinase that senses host signals and triggers 
the transition of Blastomyces dermatitidis from mold to yeast 
form [6].
Pathogenesis
Blastomycosis pulmonary infection occurs by inhalation of the 
conidia of Blastomyces dermatitidis.  The conidia convert to 
yeast phase in the lung.  The yeast forms are more resistant to 
phagocytosis and killing [7].
This is an important step in terms of pathogenesis because 
this conversion results in a survival advantage and probably 
contributes to infection by Blastomyces dermatitidis.
Blastomycosis is a systemic pyogranulomatous infection. 
The typical inflammatory response consists of clusters of 
neutrophils and noncaseating granulomas with epithelioid 
and giant cells. This response is similar to that seen with other 
dimorphic fungi including coccidioidomycosis, histoplasmosis, 
and sporotrichosis.
Clinical Manifestations
The clinical spectrum of blastomycosis is varied, including 
asymptomatic infection, acute or chronic pneumonia, 
extrapulmonary and disseminated disease [8].  The lungs are 
the most common site of infection, followed by the skin, bones, 
and genitourinary system in decreasing order of frequency [9]. 
A subset of individuals with acute pulmonary blastomycosis 
can progress to fulminant multi-lobar pneumonia and acute 
respiratory distress syndrome [10].  Diagnostic delays are 
not uncommon and often result in increased morbidity and 
mortality.
Acute infection is frequently unrecognized unless related to a 
cluster of cases or group exposure. The signs and symptoms of 
acute pulmonary blastomycosis usually begin abruptly and may 
be indistinguishable from viral or bacterial pneumonia [8].  Acute 
blastomycosis may mimic other diseases [11].  This is due to the 
variability of the presentation of blastomycosis and its relative 
rarity.  Our case is an example of how clinical presentation of 
acute pulmonary blastomycosis may be initially considered as 
community-acquired bacterial or viral pneumonia. 
Acute pulmonary blastomycosis can also present with varied 
radiographic findings.  Alveolar infiltrates with or without 
cavitation, mass lesions, and fibronodular infiltrates are most 
common [8, 9].  The radiographic findings in our patient 
included lobar and segmental alveolar infiltrates progressing 
to cavitation, fibronodular infiltrates, tree in bud opacities, 
hilar and mediastinal adenopathy, pleural effusion and diffuse 
bilateral pulmonary involvement from presumed endobronchial 
spread.   
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Spontaneous resolution of acute pulmonary blastomycosis 
has been reported, but its frequency is unknown [1, 12-14]. 
Although it has been reported that pulmonary blastomycosis in 
some patients may resolve without therapy, our case reminds 
us that previously healthy patients can have progression of 
acute pulmonary blastomycosis.  Hence, our case highlights the 
importance of prompt diagnosis and institution of treatment in 
all patients suspected to have acute pulmonary blastomycosis. 
Also, cases have been reported where treatment of acute 
pulmonary blastomycosis was withheld and patients later 
presented with extra-pulmonary disease [15].
Though our patient did not develop severe respiratory failure 
despite bilateral pulmonary involvement and endobronchial 
spread of the lungs, blastomycosis is known to cause acute 
respiratory distress syndrome with a high morbidity and 
mortality [10] and therefore an early diagnosis coupled with 
prompt treatment may lead to favorable outcomes.
Diagnosis
Due to the variability of the presentation of blastomycosis and 
its relative rarity, a high index of suspicion and appropriate 
microbiologic and histologic evaluation should be performed 
when the diagnosis is uncertain and patients live in or have 
traveled to areas endemic for blastomycosis. 
No clinical syndrome or radiological features are absolutely 
diagnostic of blastomycosis.  The spectrum of disease that 
Blastomyces dermatitidis causes overlaps with those of other 
fungal pathogens and malignancy.  Hence definitive diagnosis 
requires the growth of the organism from clinical specimens 
[8].  Unlike some fungi such as candida species, colonization 
or contamination with Blastomyces dermatitidis does not 
occur, which means that visualizing the organism on histology 
or obtaining a positive culture confirms the diagnosis of 
blastomycosis. 
A presumptive diagnosis may be made by visualization of 
the characteristic yeast form in clinical specimens including 
histopathology or by culture of the organism in body fluids or 
tissue.  In the appropriate clinical setting, visualization of the 
fungus can prompt the initiation of antimicrobial therapy. 
Diagnosis can be established by examination of wet preparations 
of clinical specimens (10% KOH and/or calcofluor white) but 
they have a low diagnostic yield (36-46%) [16]. Despite these 
low diagnostic results, the simplicity and the low cost of the 
procedure, as well as the potential for rapid diagnosis, justify a 
wet preparation on all clinical specimens. 
Cytology has been shown to be particularly useful in diagnosis, 
permitting identification of the etiologic agent in 56% of 
all cases and 72% of pulmonary cases of blastomycosis in 
a retrospective study [17].  When visualized, the yeast cells 
are easily differentiated from others on the basis of their size 
(8–15 µm in diameter), multinucleate with thick refractile cell 
wall, and single, broad-based buds.  Bronchoscopy is useful 
for diagnosis, especially in patients who are not producing 
sputum or in whom the radiograph indicates the possibility of 
malignancy [16].  Bronchial washings, lavage fluid, and post-
bronchoscopy sputum samples should be sent for cytology 
as well as smear and culture because the organism is often 
visualized on Papanicolaou preparations [18].  Papanicolaou 
staining of respiratory tract specimens has a high diagnostic 
yield (93%); the organism appears to be refractile and pale blue-
green with this stain. 
A pyogranulomatous tissue response is frequently seen in 
blastomycosis and should signal the possibility of this fungus. 
The characteristic host response to infection with Blastomyces 
dermatitidis is a mixed inflammatory reaction with clusters 
of polymorphonuclear leukocytes and granulomas, usually 
noncaseating, with epitheloid histiocytes and giant cells, 
primarily the foreign body type.
Identification of Blastomyces dermatitidis in hematoxylin-eosin 
(H & E) stained histopathologic specimens is often difficult, and 
special stains, such as Gomori methenamine-silver (GMS) or 
periodic acid-Schiff (PAS) are useful in examining the tissue for 
the presence of fungal elements.  Serology is not useful for the 
diagnosis of blastomycosis due to high degree of cross-reactivity 
shared by other endemic mycoses especially Histoplasma 
capsulatum [19, 20].  The urine of patients with blastomycosis 
may contain cross-reactive or shared antigens with H. 
capsulatum var. capsulatum; in one study, 12 of 19 patients 
with blastomycosis tested positive with the H. capsulatum urine 
antigen assay [20].  This was noted in our case as well. 
Although not an antigen test, detection of (1-3)-Beta-D-Glucan 
in serum has been shown to be a useful adjunct for diagnosis of 
invasive fungal infections, especially candidiasis, aspergillosis, 
and histoplasmosis [21-23].  In contrast, preliminary data 
suggest that the test is not of value with patients with 
blastomycosis.  In a very small study of four patients with 
microbiologically proven Blastomyces dermatitidis infection, 
(1-3)-Beta-D-Glucan was detected in only one patient, who had 
chronic disseminated disease with multiple skin lesions [24]. 
Our patient had a strongly positive (1-3)-Beta-D-Glucan. 
Culture of Blastomyces dermatitidis from environmental 
sources remains difficult, in patients with pulmonary 
blastomycosis, sputum culture has a high positive yield (e.g., 
75% per single sample, 86% per patient) [16].  Specimens 
obtained for culture by bronchoscopy yielded a positive 
diagnosis in 92% of patients.  Any material obtained should be 
placed on Sabouraud agar or, preferably, more enriched agar 
(e.g., Sabhi, brain-heart infusion, Gorman medium).  Because 
initial growth is more dependable at 30°C, this temperature 
is recommended.  Specimens contaminated with bacteria 
should also be cultured on medium containing an antibacterial 
antibiotic such as chloramphenicol.  The mycelial form of 
Blastomyces dermatitidis is not diagnostic, and conversion to 
the yeast form is required for confirmation. Early identification 
of mycelial cultures is possible with commercially available 
chemiluminescent DNA probes that recognize unique RNA 
sequences of Blastomyces dermatitidis [25].
Differential Diagnosis
Endospores of Coccidioides immitis may resemble single yeast 
cells, but the presence of budding can be used to distinguish 
Blastomyces dermatitidis.  While yeast forms of Blastomyces 
dermatitidis as described in our case report, show broad based 
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budding, Paracoccidioides brasiliensis, rarely seen in the 
United States, is distinguished by the presence of multiple, 
narrow-based buds. Blastomyces dermatitidis may sometimes 
be as small as Cryptococcus neoformans, although the capsule 
and narrow-based bud of the latter, aid in differentiation.
Treatment
The greatest challenge in making the diagnosis of blastomycosis 
is considering it in the first place.   Although the disease can be 
fatal, most patients are cured with antifungal therapy.
Before the availability of chemotherapy for treatment of 
blastomycosis, the disease as reported had a progressive course 
with eventual extrapulmonary disease and a mortality rate 
exceeding 60%.  Even though isolated cutaneous disease had a 
better prognosis, skin lesions were progressive, and spontaneous 
recovery was uncommon.  Thus, after the introduction of 
effective antifungal therapy, it was accepted that all patients 
with blastomycosis should be treated.
Amphotericin B (AmB) was previously considered the 
treatment of choice for all clinical forms of blastomycosis [26, 
27].  However, ketoconazole, itraconazole, and fluconazole are 
effective alternatives for immunocompetent patients with mild 
to moderate disease.
The Infectious Diseases Society of America (IDSA) has 
published clinical practice guidelines that are based upon open-
label studies, case reports, and expert opinion.
AmB remains the drug of choice for blastomycosis with life 
threatening disease or with central nervous system involvement, 
for patients who are immunocompromised or for whom azole 
treatment has failed [27].
For moderate to severe pulmonary disease, current guidelines 
recommend treatment with a lipid formulation of AmB at a 
dosage of 3–5mg/kg per day intravenous or AmB deoxycholate 
at a dosage of 0.7–1mg/kg per day intravenous for 1-2 weeks or 
until improvement is noted, followed by oral itraconazole [27]. 
However, the cost and toxicity are substantial, especially of AmB 
deoxycholate.  Among the azole antifungals, ketoconazole was 
the first one used with success in treatment of blastomycosis. 
However, in the current IDSA guidelines for Blastomycosis, 
itraconazole has replaced ketoconazole as the azole of choice for 
its better antimycotic effect, better tolerability, and higher (up to 
95%) rate of cure [27].  Treatment duration is 6–12 months or 
till resolution of radiological abnormalities.
Current guidelines recommend step-down therapy to an 
azole after an initial therapeutic response to AmB.  Patients 
who are immunocompetent and do not have central nervous 
system disease may be switched to step-down therapy of oral 
itraconazole, 200 mg orally three times daily for three days, 
followed by 200 mg twice daily for 6 to 12 months [27].  Relapse 
rates of most patients treated with AmB are <5%. Relapse is 
more common in immunocompromised patients, especially 
those with acquired immune deficiency syndrome [27].  Some 
authorities recommend lifelong suppressive therapy with 
itraconazole [27].  These patients still require close follow-up.
Prevention
Vaccine to prevent blastomycosis is not available.  There is 
no data to suggest that modifying individual behavior would 
change the incidence of the blastomycosis [11].  Blastomyces 
dermatitidis is not transmitted from person to person, and 
therefore, blastomycosis is generally not contagious. Pets, 
particularly dogs, can get blastomycosis, but it is not contagious 
between animals and people [28].  Blastomycosis is uncommon, 
even in areas in which the disease is endemic. 
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